Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
GLAXOSMITHKLINE PLC
SIC 2834 · Pharmaceutical Preparations
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
GLAXOSMITHKLINE PLC
SIC 2834 · Pharmaceutical Preparations
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
GLAXOSMITHKLINE PLC
SIC 2834 · Pharmaceutical Preparations
Notes
Support
about
terms
$
GLAXF
GLAXOSMITHKLINE PLC
CIK:
0001131399
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.25.4
Consolidated income statement - GBP (£)
£ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Profit or loss [abstract]
Turnover
£ 32,667
£ 31,376
£ 30,328
Cost of sales
(9,017)
(9,048)
(8,565)
Gross profit
23,650
22,328
21,763
Selling, general and administration
(9,088)
(11,015)
(9,385)
Research and development
(7,525)
(6,401)
(6,223)
Royalty income
879
639
953
Other operating income/(expense)
16
(1,530)
(363)
Operating profit
7,932
4,021
6,745
Finance income
169
122
115
Finance expense
(701)
(669)
(792)
Share of after tax profit/(loss) of associates and joint ventures
1
(3)
(5)
Profit/(loss) on disposal of interests in associates and joint ventures
0
6
1
Profit before taxation
7,401
3,477
6,064
Taxation
(1,112)
(526)
(756)
Profit after taxation
6,289
2,951
5,308
Profit attributable to non-controlling interests
573
376
380
Profit attributable to shareholders
£ 5,716
£ 2,575
£ 4,928
Basic earnings per share (pence) (in pence per share)
£ 1.411
£ 0.632
£ 1.216
Diluted earnings per share (pence) (in pence per share)
£ 1.388
£ 0.622
£ 1.199
v3.25.4
Consolidated cash flow statement
£ in Millions
12 Months Ended
Dec. 31, 2025
GBP (£)
Dec. 31, 2024
GBP (£)
Dec. 31, 2023
GBP (£)
Cash flow from operating activities
Total profit for the year
£ 6,289
£ 2,951
£ 5,308
Adjustments reconciling profit after tax to operating cash flows
2,654
4,910
2,788
Cash generated from operations
8,943
7,861
8,096
Taxation paid
(1,202)
(1,307)
(1,328)
Total net cash inflow/(outflow) from operating activities
7,741
6,554
6,768
Cash flow from investing activities
Purchase of property, plant and equipment
(1,348)
(1,399)
(1,314)
Proceeds from sale of property, plant and equipment
24
65
28
Purchase of intangible assets
(1,637)
(1,583)
(1,030)
Proceeds from sale of intangible assets
115
131
12
Purchase of equity investments
(92)
(103)
(123)
Proceeds from sale of equity investments
189
2,356
1,832
Share transactions with non-controlling interests
0
(1)
0
Purchase of businesses, net of cash acquired
(1,692)
(805)
(1,457)
Investments in associates and joint ventures
0
(43)
0
Proceeds from disposal of associates and joint ventures
0
0
1
Contingent consideration paid
(17)
(19)
(11)
Disposal of businesses
(27)
(18)
49
Interest received
154
138
115
(Increase)/decrease in liquid investments
11
21
72
Dividends from joint ventures and associates
67
15
11
Dividend and distributions from investments
20
16
220
Total net cash inflow/(outflow) from investing activities
(4,233)
(1,229)
(1,595)
Cash flow from financing activities
Issue of share capital
15
20
10
Repayment of long-term loans
(1,400)
(1,615)
(2,260)
Issue of long-term notes
1,979
1,075
223
Net increase/(decrease) in short-term loans
1,085
(811)
(333)
Increase in other short-term loans
130
266
0
Repayment of other short-term loans
(288)
(81)
0
Repayment of lease liabilities
(241)
(226)
(197)
Interest paid
(679)
(632)
(766)
Dividends paid to shareholders
(2,564)
(2,444)
(2,247)
Purchase of treasury shares
(1,377)
0
0
Distribution to non-controlling interests
(391)
(416)
(412)
Contributions from non-controlling interests
0
9
7
Other financing items
46
129
334
Total net cash inflow/(outflow) from financing activities
(3,685)
(4,726)
(5,641)
Increase/(decrease) in cash and bank overdrafts in the year
(177)
599
(468)
Cash and bank overdrafts at the beginning of the year
3,403
2,858
3,425
Exchange adjustments
(19)
(54)
(99)
Increase/(decrease) in cash and bank overdrafts in the year
(177)
599
(468)
Cash and bank overdrafts at the end of the year
3,207
3,403
2,858
Cash and bank overdrafts at end of the year comprise:
Cash and cash equivalents
3,397
3,870
2,936
Bank overdrafts
(190)
(467)
(78)
Cash and bank overdrafts
£ 3,207
£ 3,403
£ 2,858
v3.25.4
Consolidated balance sheet - GBP (£)
£ in Millions
Dec. 31, 2025
Dec. 31, 2024
Non-current assets
Property, plant and equipment
£ 9,322
£ 9,227
Right of use assets
726
846
Goodwill
7,018
6,982
Other intangible assets
16,748
15,515
Investments in associates and joint ventures
89
96
Other investments
1,037
1,100
Deferred tax assets
6,520
6,757
Derivative financial instruments
0
1
Other non-current assets
2,148
1,942
Total non-current assets
43,608
42,466
Current assets
Inventories
5,924
5,669
Current tax recoverable
288
489
Trade and other receivables
7,471
6,836
Derivative financial instruments
121
109
Liquid investments
9
21
Cash and cash equivalents
3,397
3,870
Assets held for sale
300
3
Total current assets
17,510
16,997
Total assets
61,118
59,463
Current liabilities
Short-term borrowings
(3,012)
(2,349)
Contingent consideration liabilities
(1,348)
(1,172)
Trade and other payables
(15,381)
(15,335)
Derivative financial instruments
(75)
(192)
Current tax payable
(498)
(703)
Short-term provisions
(938)
(1,946)
Liabilities relating to assets held for sale
(139)
0
Total current liabilities
(21,391)
(21,697)
Non-current liabilities
Long-term borrowings
(14,708)
(14,637)
Deferred tax liabilities
(291)
(382)
Pensions and other post-employment benefits
(1,687)
(1,864)
Derivative financial instruments
(67)
0
Other provisions
(610)
(589)
Contingent consideration liabilities
(5,385)
(6,108)
Other non-current liabilities
(1,023)
(1,100)
Total non-current liabilities
(23,771)
(24,680)
Total liabilities
(45,162)
(46,377)
Net assets
15,956
13,086
Equity
Share capital
1,349
1,348
Share premium
3,498
3,473
Retained earnings
10,209
7,796
Other reserves
1,321
1,054
Shareholders’ equity
16,377
13,671
Non-controlling interests
(421)
(585)
Total equity
£ 15,956
£ 13,086